The Army is not properly monitoring the prescribing of medications to treat post-traumatic stress disorder (PTSD) in active-duty soldiers to ensure that antipsychotics and sedatives are not being used, a new government report says. The report by the Government Accountability Office (GAO) recommends that the Secretary of Defense direct the Army to monitor prescribing practices in order to detect medications that are discouraged under PTSD treatment guidelines. Those guidelines caution against the use of antipsychotics and benzodiazepines, a class of sedatives, because of their ineffectiveness and potential risk. “The Army does not monitor the prescribing of medications to treat PTSD on an ongoing basis,” says the report, led by the GAO’s director of health care, Debra Draper. “Without such monitoring, the Army may be unable to identify and address practices that are inconsistent with the guideline.”
The Department of Defense did not dispute the GAO recommendations, but argued that it has worked to reduce antipsychotic prescribing.